Presentation Time: 9:00 a.m. (Eastern) Tuesday, April 27, 2004
DENVER, April 21 /PRNewswire-FirstCall/ -- Myogen, Inc. (Nasdaq: MYOG), a
biopharmaceutical company focused on the discovery, development and
commercialization of small molecule therapeutics for the treatment of
cardiovascular disease, today announced that J. William Freytag, President and
CEO, will present a corporate overview at the CIBC World Markets Biotechnology
& Specialty Pharmaceuticals Conference.
The presentation will take place at 9:00 a.m. (Eastern) on Tuesday,
April 27, 2004 in the Millennium Broadway Hotel, 145 West 44th Street, New
York, New York 10036. There will be a live webcast of the presentation from
the conference. The webcast will be accessible through a link posted on the
investor relations section of the Myogen website at
http://investor.myogen.com/. The webcast will be available for replay on
Myogen's website through May 14, 2004.
Myogen is a biopharmaceutical company focused on the discovery,
development and commercialization of small molecule therapeutics for the
treatment of cardiovascular disorders. Myogen currently markets one product
in Europe for the treatment of acute decompensated heart failure and has three
product candidates in late-stage clinical development: enoximone capsules for
the treatment of chronic heart failure, ambrisentan for the treatment of
pulmonary arterial hypertension and darusentan for the treatment of resistant
hypertension. The Company also conducts a target and drug discovery research
program focused on the development of disease-modifying drugs for the
treatment of chronic heart failure and related cardiovascular disorders.
Please visit our website at http://www.myogen.com.
Safe Harbor Statement
This press release and the anticipated presentation contain forward-
looking statements that involve significant risks and uncertainties, including
those discussed in this release, those to be discussed in the presentation and
others that can be found in the "Risk Factors" section of Myogen's Annual
Report on Form 10-K filed on March 1, 2003. Myogen does not undertake any
obligation to update any forward-looking statements contained in this document
or the anticipated presentation as a result of new information, future events
or otherwise. The Company cautions investors not to place undue reliance on
the forward-looking statements contained in this press release or the
presentation. No forward-looking statement can be guaranteed and actual
events and results may differ materially from those projected.
SOURCE Myogen, Inc.
 back to top
Related links:
http://investor.myogen.com
http://www.myogen.com
CONTACT:
Derek K. Cole, Director, Investor Relations
of Myogen, Inc., +1-303-464-3986, derek.cole@myogen.com
|
